tbuckley/cabot-search huggingface dataset:
Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).
Authors: Min Kyoung Kim, Cheolwon Suh, Chang-Ki Min, Seok Jin Kim, Kihyun Kim, Joon Ho Moon, Sung-Soo Yoon, Gyeong-Won Lee, Hye Jin Kang, Sung Hyun Kim, Chul Won Choi, Hyeon Seok Eom, Jae-Yong Kwak, Hyo Jung Kim, Yeung-Chul Mun, Soo-Mee Bang, Keehyun Lee, Ho Jin Shin, Deok Hwan Yang, Jae Hoon Lee
Journal: Blood (2009)
Complete Block of Early B Cell Differentiation in Mice Lacking the Endosomal Adaptor Protein p14
Authors: Marcin Lyszkiewicz, Daniel Kotlarz, Natalia Zietara, Gudrun Brandes, Jana Diestelhorst, Silke Glage, Eliash Hobeika, Michael Reth, Lukas Huber, Andreas Krueger, Christoph Klein
Journal: Blood (2015)
Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)
Authors: S. L. Galper, H. Deshpande, M. G. Rose, R. H. Decker
Journal: Journal of Clinical Oncology (2009)

e17030 Background: Concurrent chemoradiation of LAHNC with cetuximab or cisplatin improves survival. The purpose of this study is to compare cetuximab chemoradiation (ExRT) with cisplatin chemoradiation (ChRT) in patients treated with IMRT. Methods: Between January 2005 and August 2008, 24 patients with LAHNC were treated with definitive chemoradiation utilizing IMRT. ExRT was reserved for those whose age or comorbidities precluded ChRT. 15 patients were treated with ChRT and 9 patients were treated with ExRT. Patient charts and Tumor Registry data were reviewed for acute and late toxicity and for local/regional failure (LRF), distant metastases and death. Results: The ExRT cohort was significantly older (median age 71 vs 58, p=0.005) and had more larynx/hypopharynx primaries (44% vs 27%). The cohorts were otherwise balanced with respect to T- and N-stage. Median follow-up for the ExRT and ChRT cohorts was 11 and 12 months, respectively. Overall treatment time in compliant patients was lower in ExRT patients (46 vs 50 days, p=0.05), reflecting increased use of accelerated radiation fractionation (66% vs 40%). See Table for toxicity outcomes. There was a trend toward increased ≥G3 acute mucositis in the ExRT group (p=0.07). However, there was less weight loss (p=0.05). There were similar acute epidermitis and hospitalizations for malnutrition/hydration rates and a nonsignificant decrease in prolonged mucosal toxicity. 1 patient developed skin necrosis and another osteoradionecrosis in the ChRT group. 1-year freedom from LRF was 89% in the ChRT group vs 56% in the ExRT group (p=0.07). Overall survival (OS) at 1 year was 100% (ChRT) vs 88% (ExRT). Conclusions: ExRT showed a trend toward worse acute mucosal toxicity but not late toxicity despite increased rates of altered fractionation with a higher daily dose. ExRT was associated with worse LRC and OS. A randomized study would best compare outcomes and toxicity profiles. Until such analysis, cetuximab should be reserved for patients unable to tolerate ChRT. [Table: see text] No significant financial relationships to disclose.
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.
Authors: John C. Araujo, Geralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goebell, Johann Sebastian De Bono, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher Logothetis
Journal: Journal of Clinical Oncology (2013)

LBA8 Background: SRC kinases may contribute to androgen independence of mCRPC.Dasatinib (DAS) inhibits tyrosine kinases including SRC kinases with preclinical evidence for antimetastatic activity, inhibition of osteoclast function in tumor microenvironment, and synergistic activity with docetaxel (D). In phase I/II trials of mCRPC patients (pts), DAS in combination with D had an acceptable safety profile with objective response rates (ORR) improved over historical data and decreased levels of bone turnover markers. Methods: READY was a multinational, randomized, double-blinded, placebo-controlled, phase III study. Pts with mCRPC (n = 1,522) were randomized (1:1) to receive either D 75 mg/m 2 q3wk + prednisone with double-blinded DAS 100 mg qd (DAS/D, n = 762) or placebo (PBO/D, n = 760). Primary endpoint was overall survival (OS). Secondary endpoints were ORR, time to first skeletal-related event (TFSRE), time to prostate-specific antigen progression (TPSAP), urinary N-telopeptide (uNTX) reduction, pain reduction, progression-free survival (PFS), and safety. Results: No OS difference between DAS/D and PBO/D (median, 21.5 vs. 21.2 mos; hazard ratio [HR], 0.99; log-rank P = 0.90) was observed. Results of secondary endpoints for DAS/D vs. PBO/D were: ORR (30.5 vs. 31.9%); TFSRE (median, not reached vs. 31.1 mos; HR, 0.81 [95% CI, 0.64-1.02]); uNTX reduction (66.0 vs. 60.6%); PFS (median, 11.8 vs. 11.1 mos; HR, 0.92); TPSAP (median, 8.0 vs. 7.6 mos; HR, 0.91), and pain reduction (66.6 vs. 71.5%). Twenty-three percent of DAS/D and 14% of PBO/D pts received therapy for &lt;3 mos. Most common AEs in DAS/D arm included diarrhea, fatigue, alopecia, and nausea. Grade 3-4 AEs of interest for DAS/D vs. PBO/D included anemia (8.0 vs.5.9%), neutropenia (6.2 vs. 5.5%), hypocalcemia (3.5 vs.3.1%), GI bleeding (2.6 vs.1.3%), and pleural effusion (1.3 vs. 0.4%). Conclusions: The addition of DAS to standard-of-care chemotherapy in mCRPC pts did not improve OS. There was a modest reduction in the risk of TFSRE with DAS/D vs. PBO/D. With a median follow-up of 19 mos of 761 DAS/D-treated pts, no unexpected toxicities for DAS were observed. Clinical trial information: NCT00744497.
The role of maintenance therapy in multiple myeloma
Authors: B Lipe, R Vukas, J Mikhael
Journal: Blood Cancer Journal (2016)

Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma.
Tiny microbes, enormous impacts: what matters in gut microbiome studies?
Authors: Justine Debelius, Se Jin Song, Yoshiki Vazquez-Baeza, Zhenjiang Zech Xu, Antonio Gonzalez, Rob Knight
Journal: Genome biology (2016)

Many factors affect the microbiomes of humans, mice, and other mammals, but substantial challenges remain in determining which of these factors are of practical importance. Considering the relative effect sizes of both biological and technical covariates can help improve study design and the quality of biological conclusions. Care must be taken to avoid technical bias that can lead to incorrect biological conclusions. The presentation of quantitative effect sizes in addition to P values will improve our ability to perform meta-analysis and to evaluate potentially relevant biological effects. A better consideration of effect size and statistical power will lead to more robust biological conclusions in microbiome studies.
Delivering on the promise of precision cancer medicine
Authors: Michael F. Berger, Eliezer M. Van Allen
Journal: Genome Medicine (2016)

The emerging paradigm of precision cancer medicine, in which the use of molecular data at the point of care directly impacts patient treatment and clinical decision-making, has already had a substantial, direct clinical impact on many aspects of medical oncology. Advances in precision cancer medicine include well-established molecularly targeted therapies for patients with BRAF-mutant metastatic melanoma [1], those with EGFR-mutant [2] or ALK-mutant [3] non-small-cell lung cancer, and those with BCR–ABL-translocation-positive chronic myelogenous leukemia [4]. In addition, the introduction of large-scale genomic technologies at the point of care [5–7] has catalyzed discoveries in translational oncology and is driving new research that aims to dissect selective responses to targeted, immune-driven therapies and to chemotherapies, as well as identifying novel targets for which therapies are now in development. Indeed, propelled by the ability to generate increasingly complex molecular data directly from patient tumor and germ-line samples, the cycle of translating discoveries into clinical practice may be accelerating.
Characterization of Phenotypic and Transcriptional Differences in Human Pluripotent Stem Cells under 2D and 3D Culture Conditions
Authors: Ken‐ichiro Kamei, Yoshie Koyama, Yumie Tokunaga, Yasumasa Mashimo, Momoko Yoshioka, Christopher Fockenberg, Rowland Mosbergen, Othmar Korn, Christine Wells, Yong Chen
Journal: Advanced Healthcare Materials (2016)

Human pluripotent stem cells hold great promise for applications in drug discovery and regenerative medicine. Microfluidic technology is a promising approach for creating artificial microenvironments; however, although a proper 3D microenvironment is required to achieve robust control of cellular phenotypes, most current microfluidic devices provide only 2D cell culture and do not allow tuning of physical and chemical environmental cues simultaneously. Here, the authors report a 3D cellular microenvironment plate (3D-CEP), which consists of a microfluidic device filled with thermoresponsive poly(N-isopropylacrylamide)-β-poly(ethylene glycol) hydrogel (HG), which enables systematic tuning of both chemical and physical environmental cues as well as in situ cell monitoring. The authors show that H9 human embryonic stem cells (hESCs) and 253G1 human induced pluripotent stem cells in the HG/3D-CEP system maintain their pluripotent marker expression under HG/3D-CEP self-renewing conditions. Additionally, global gene expression analyses are used to elucidate small variations among different test environments. Interestingly, the authors find that treatment of H9 hESCs under HG/3D-CEP self-renewing conditions results in initiation of entry into the neural differentiation process by induction of PAX3 and OTX1 expression. The authors believe that this HG/3D-CEP system will serve as a versatile platform for developing targeted functional cell lines and facilitate advances in drug screening and regenerative medicine.
Comparing a Novel PET Agent, Yttrium-86 Oxine, with Biopsy and FACS Analysis for Tracking in Vivo Migration Patterns of Different Preparations of DC from a Single Donor
Authors: Si mon J. Harrison, Mick Thompson, Dominic Wall, Maureen Loudovaris, Andreas Mackensen, Jacques Bartholeyns, Maria Ferrantini, Laura Santodonato, Thomas Felzmann, Rod Hicks, H. Miles Prince, David Ritchie
Journal: Blood (2008)
Effect of bispecific antisense oligos on prostate cancer cell growth
Authors: M. Rubenstein, P. Tsui, K. A. Christensen, P. Guinan
Journal: Journal of Clinical Oncology (2007)

14034 Background: Antisense oligos against TGF-a (MR 1 ), EGFR (MR 2 ), and bcl-2 (MR 4 ) are efficacious against prostate tumors. Methods: To enhance activity “bispecifics” were constructed. A pair recognized TGF-a and EGFR mRNA binding sites (TGF-a/EGFR [MR 12 ] and EGFR/TGF-a [MR 21 ]), another pair EGFR and bcl-2 (EGFR/bcl-2 [MR 24 ] and bcl-2/EGFR [MR 42 ]). Pairs differ in 5’ to 3’ binding site orientation, and were tested in vitro against prostate tumor cells. Following cell attachment, incubations were for 2 days with the agents followed by 2 days in their absence. Results: Bispecifics (6.25uM) are at least as effective as monospecifics and EGFR contributed to most first pair activity. Against PC-3 and LNCaP cells, MR 2 , MR 4, MR 12, MR 21 , MR 24 and MR 42 significantly inhibited growth. PC-3 cells were then incubated ± a chemotherapeutic agent. With LD 50 Cytoxan, MR 2 , MR 4 , MR 24 , MR 42 significantly inhibited 47.3, 45.7, 68.3 and 64.9%; with LD 50 Taxol MR 2 , MR 4 , MR 24 , MR 42 significantly inhibited 49.8, 45.8, 64.1 and 59.2%; and with LD 50 DES MR 2 , MR 4 , MR 24 , MR 42 significantly inhibited 66.6, 67.6, 64.3 and 67.2% respectively. Each agent significantly increased the inhibition produced by either oligo alone. LNCaP cells were also incubated with mono- and bispecific oligos ± chemotherapeutics. MR 2 , MR 4 , MR 24 , MR 42 produced significant inhibitions of 57.4, 58.4, 69.4 and 68.6% for Cytoxan; 70.4, 70.1, 73.6 and 74.0% for Taxol; and 49.8, 50.1, 59.6 and 53.9% respectively for DES. A complete PC-3 experiment compared MR 1 , MR 2 , MR 4, MR 12, MR 21 , MR 24 and MR 42 in the presence of LD 50 Cytoxan. Each oligo combined with Cytoxan significantly inhibited: MR 1 by 51.0, MR 2 by 55.0, MR 4 by 58.0; MR 12 by 56.0; MR 21 by 61.1, MR 24 by 65.5 and MR 42 by 66.0%. Bispecifics directed against two different pathways, MR 24 and MR 42 were the most effective. A complete LNCaP experiment compared the same series of oligos in the presence of LD 50 Cytoxan. Each oligo combined with Cytoxan significantly inhibited: MR 1 by 49.0, MR 2 by 50.0, MR 4 by 53.0; MR 12 by 52.0; MR 21 by 58.6, MR 24 by 53.9 and MR 42 by 58.0%. Conclusions: Bispecific oligos significantly advance antisense technology and could play a role treating prostate cancer, particularly when combined with chemotherapy. Bispecifics against proteins associated with different growth pathways may be best. No significant financial relationships to disclose.
Prediction of Postoperative Intraocular Lens Position with Angle-to-Angle Depth Using Anterior Segment Optical Coherence Tomography
Authors: So Goto, Naoyuki Maeda, Shizuka Koh, Kazuhiko Ohnuma, Kenichi Hayashi, Ikko Iehisa, Toru Noda, Kohji Nishida
Journal: Ophthalmology (2016)
Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies
Authors: S. E. Schild, Y. Qi, A. D. Tan, S. J. Mandrekar, A. A. Adjei, J. E. Krook, K. M. Rowland, Y. I. Garces, G. S. Soori, J. A. Sloan
Journal: Journal of Clinical Oncology (2008)

8076 Background: To assess the prognostic importance of pre-treatment patient-reported QOL assessments for OS in the presence of other known prognostic factors including performance status, age, gender, hemoglobin level, absolute neutrophil count, and Body Mass Index (BMI) in A-NSCLC. Methods: 373 pts with A-NSCLC (stages IIIb with pleural effusion & IV) from 6 NCCTG trials were included. Treatment included various combinations of the following agents: vinblastine, adriamycin, cisplatin, filgrastim, edatrexate, LU 103793, docetaxel, gemcitabine, vinorelbine gefitinib, paclitaxel, carboplatin, and carboxyamino-triazole. QOL assessments included the single item Uniscale (355 pts), Lung Cancer Symptom Score (LCSS:217 pts), & Functional Assessment of Cancer Therapy-Lung (FACT-L:197 pts). All QOL scores were transformed to a 0–100 scale (higher is better), and categorized using the sample median (≤median vs. >median) or clinically deficient score (≤50 vs. >50). Univariate and multivariate Cox Proportional Hazards Model were used to evaluate the prognostic importance of all factors on OS. Results: The pre-treatment LCSS total score (p=0.06, Hazard Ratio (HR)=1.4), and FACT-L total score (p=0.09, HR =1.3,) were not significant predictors of OS. Pre-treatment pt QOL assessed by Uniscale was a significant predictor of OS univariately (p<0.0001 ). Uniscale (p<0.0001; HR=1.6 for sample median and 2.0 for clinically deficient categorization) and BMI (p<0.01) were the only significant predictors of OS in the multivariate analysis. The median OS for pts that had a clinically deficient Uniscale score (≤ 50) was 5.6 months(m) vs. 11.0 m for the > 50 group; and the median OS for pts with a uniscale score less than the median (83) was 7.7 m vs. 12.8 m for the > 83 group. Conclusions: Pt QOL measured by Uniscale is a significant and strong prognostic factor for OS in A-NSCLC in the presence of other known factors such as PS, age, gender and BMI. This factor should be integrated as a stratification factor for future trial design in A-NSCLC because it can identify pts with OS more divergent than currently available therapies. No significant financial relationships to disclose.
GW26-e3858 Repeated acute embolism of superior mesenteric artery due to atrial fibrillation: a case report and review of the literatures
Authors: Yingxiong Huang, Zi YE, Zi-yu Zheng, Hong Zhan, Jiang-hui Liu, Guang-qi Chang, Hong Zhan
Journal: Journal of the American College of Cardiology (2015)
Analysis of microRNA Patterns in Hodgkin’s Lymphoma (HL).
Authors: Alfons Navarro, Anna Gaya, Aina Pons, Pau Abrisqueta, Bernat Gel, Antonio Martinez, Armando Lopez-Guillermo, Carmen Martinez, Miquel Granell, Rosa Artells, Sonia Jansa, Alvaro Urbano-Ispizua, Emili Montserrat, Mariano Monzo
Journal: Blood (2006)
High Engraftment Rate after Second Stem Cell Transplantation for Thalassemia: A Prospective Study.
Authors: Javid Gaziev, Guido Lucarelli, Pietro Sodani, Paola Polchi, Katia Paciaroni, Marco Marziali, Antonella Isgro, Cecilia Alfieri, Maria Domenica Simone, Andrea Roveda, Aldo Montuoro, Gioia De Angelis, Cristiano Gallucci
Journal: Blood (2007)
GW26-e2244 Gene Mutations in Chinese with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy-a cohort registry study
Authors: Xiaoliang Qiu, Xin Liu, Cuilan Li, Xuguang Qin, Tiangang Zhu, Fujun Wang, Li Zhang, Dayi Hu, Yuxin Fan, Wenling Liu
Journal: Journal of the American College of Cardiology (2015)
Cavitary lung cancer with cartilage tissues in the wall mimicking aspergilloma
Authors: Takashige Taoka, Tsutomu Shinohara, Keishi Naruse, Fumitaka Ogushi
Journal: Thorax (2016)

A 65-year-old female presented with a cavitary lesion in the right upper lung field (figure 1A). The diagnosis was aspergilloma because of the chest CT appearance of a fungus ball-like mass in the cavity (figure 1B) and treatment was started with itraconazole (200 mg/day). However, the cavitary lesion enlarged over a period of 6 months (figure 1C), with a C-reactive protein (CRP) level under 0.5 mg/dL. The patient was referred to our hospital and microscopic examination of a transbronchial lung biopsy of the cavitary lesion revealed lung cancer. A right upper lobectomy was performed. Histologically, pleomorphic carcinoma, confirmed …
The bacterial cell envelope as delimiter of anti-infective bioavailability – An in vitro permeation model of the Gram-negative bacterial inner membrane
Authors: Florian Graef, Branko Vukosavljevic, Jean-Philippe Michel, Marius Wirth, Oliver Ries, Chiara De Rossi, Maike Windbergs, Véronique Rosilio, Christian Ducho, Sarah Gordon, Claus-Michael Lehr
Journal: Journal of Controlled Release (2016)
Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).
Authors: B. Markman, C. Gomez-Roca, A. Cervantes-Ruiperez, J. Delord, L. Paz Ares, J. Soria, J. Corral, S. Hollingsworth, L. Manenti, J. Tabernero
Journal: Journal of Clinical Oncology (2010)

2522 Background: RO5083945 is a glycoengineered anti EGFR IgG1 mAb exhibiting increased binding affinity for all FcγRIIIa variants expressed on immune effector cells. RO5083945 demonstrates significantly improved cell killing in ADCC-based assays and greater activity in in vivo models compared to cetuximab and panitumumab. Hence, RO5083945 has the potential to show clinical activity in patients with solid tumors, including KRAS mutant CRC. Methods: Patients (pts) with metastatic solid tumors were enrolled into part I of a phase I/II study of three regimens (qW, q2W and q3W), exploring up to 7 dose levels (50–1400 mg) to assess PK, MTD, AEs, PD and anti-tumor activity. Results: 75 pts were enrolled. No MTD was reached. Main AEs were infusion related reactions (77% of pts; mainly during the first infusion), rash (76%; 17% grade 3) and asymptomatic hypomagnesemia (24%; mainly grade 1/2). Among evaluable pts treated at 700–1400 mg, 3 pts (6%) had a partial response (2 confirmed, 1 recently reported) and 21 pts (44%) had stable disease. 13 pts had SD/PR ≥ 4 months, 9 ongoing. Out of 23 pts who had received prior cetuximab/panitumumab + CT, 35% had a better (5 pts) or similar (3 pts) PFS on RO5083945 (400–1400 mg). A target trough concentration of 50 μ g/mL was achieved in all pts administered ≥ 700 mg/qW, and in the majority receiving 1400 mg/q2W. The PK were associated with non-linear clearance over the dose range 50–400 mg, becoming linear above 700 mg. Preliminary analysis has identified the following RO5083945-related PD effects: significantly reduced detection of natural killer (NK) cells in peripheral blood; immune cell infiltration (CD4+/8+/16+/56+/68+) with the emergence of NK cells in rash biopsies and paired tumor biopsies (n=4). Based on PK and clinical data, the recommended dose for part II of the study is 1400 mg on days 1 ' 8 followed by 1400 mg/q2W. Conclusions: RO5083945 is safe and has demonstrated clinical activity in heavily pre-treated pts including those progressing on other EGFR mAbs. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Lilly, Pfizer, Roche Amgen, Merck Serono, Roche
Weekly paclitaxel in Japanese women with metastatic or advanced breast cancer
Authors: Y. Rai, T. Tajima, K. Tamura, Y. Morishita, T. Taki, K. Hisamatsu, Y. Ito, T. Seriu
Journal: Journal of Clinical Oncology (2006)

10702 Background: Weekly administration of paclitaxel (WP) has been reported to be at least as well-tolerated and effective as conventional tri-weekly treatment (TP). The present study was to evaluate the efficacy and safety of weekly paclitaxel treatment for japanese women with metastatic or advanced breast cancer. Methods: Eligibility criteria included &lt; 75 years of age, histologically-proven advanced or recurrent breast cancer, and performance status (PS) of 0 to 2. Patients were scheduled to receive at least one course of paclitaxel 100 mg/m 2 /week for 6 consecutive weeks followed by 1 week off. The present WP results were compared with the previous TP data generated by the same trial group in Japan. In the TP group, paclitaxel 210 mg/m 2 was given every 3 weeks up to 3 cycles or more until tumor progression or severe toxicity was observed. Results: From December 2002 to July 2005, 69 patients were enrolled into the study of WP and 68 were eligible for evaluation. All were previously treated, and 51 of 69 patients (73.9%) had received anthracyclines prior to this study. The median age was 55 years (range 27–74), and 66 patients (95.7%) had PS of 0–1. Sixty nine patients have been analyzed for efficacy and toxicity by the evaluation committee. The median dose intensity was 81.25 mg/m 2 per week. In total, 270 courses of WP were administered (median 3 courses; range 1–13). Three patients entered into complete remission (CR) and 28 achieved partial response (PR) by the WHO response criteria with a response rate (RR) of 44.9%, which is similar to RR in the historical TP group (RR of 33.9% in 62 Patients). Median duration of response was 238 days (range 91–631). Time to progression was 193 days. It is of note that grade 3–4 neutropenia was observed less frequently in WP as compared with TP (37.7 vs. 93.3%). Other major toxicities including peripheral neuropathy (PNP) appear to be similar between the two regimens through all toxicity grades of PNP (WP and TP group; 89.9% and 93.3%, respectively). Conclusion: WP appears to have similar or better efficacy with better toxicity profile as TP in patients with metastatic or advanced breast cancer. No significant financial relationships to disclose.